肥胖的臨床管理：製品、技術、及市場

Products, Technologies and Markets in the U.S. and Europe in the Clinical Management of Obesity

出版商	MedMarket Diligence
出版日期	2004年09月	商品編碼	18183
內容資訊	英文 268 pages � 81 Exhibits � 34 Company Profiles
價格	本報告書已不再販售

簡介
目錄
相關商品

本報告已在2011年07月19日停止出版。

簡介

在醫療技術、醫學及輔助市場決策領域上，有不錯口碑的美國市調公司 MedMarket Diligence（總公司: 加州），詳盡地調查與分析肥胖臨床管理的技術及市場，並有系統地歸結製品、技術現況及未來，出版綜合報告書“Products, Technologies and Markets Worldwide in the Clinical Management of Obesity”。

此報告書使用包括 65 張圖表、 208 頁的篇幅，除了說明肥胖的患者人數、各種治療法的臨床管理現況及傾向、治療用各種製品的詳細內容；也探討美國及歐洲為中心的製品市場的現況與至 2013 年前的未來性、市場參與 33 家企業的檔案；另外也提供市場定位、市場整體等情報。此報告書的概略架構如下所示。

1. 簡介

概要
諸定義
臨床背景(肥胖的流行、其他)
患者族群(大人、青年、兒童)
體重過重、肥胖及罹患率(各種原因、生活型態、BED、NES、治療必要性)

2. 體重減輕管理的研究

外科手術的相關研究(BPD/DS、VBG、AGB、IGS、其他)
醫學療法
不使用醫藥的研究
醫學管理的 VLCD (超低卡洛里‧減肥)
體重管理研究

3. 肥胖的影響

肥胖治療的成本及償還
對商業/經濟的影響(保險成本、其他)
政府合作(美國、英國的 NICE、法國的 CNAM)

4. 市場分析

各國的肥胖外科手術器具
各國的肥胖用醫藥的現況及未來

5. 市場機會

醫藥及機器的市場機會
肥胖患者專用的長期性醫療機器
相互利益的關係創造
教育及實踐諮詢

6. 企業檔案( 33 家)

This report will be a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report will describe the current and projected patient population in obesity, detailing their incidence worldwide, the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches.

The report will describe clinical trends in the management of the obese. The report will detail the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and will provide current and forecast of the market for these products in the U.S. and separately for Europe. The report will profile at least 25 companies in this market, detailing the current products, products in development, market position and overall businesses in obesity management.

Executive Summary

Section 1: Introduction

1.1 Overview
1.2 Definitions
1.3 Clinical Background: 1.3.1 Prevalence in the US Population; 1.3.2 Prevalence of Obesity Worldwide; 1.3.2.1 Europe; 1.3.2.2 Japan; 1.3.2.3 China; 1.3.2.4 Developed Nations vs. Developing Nations
1.4 Patient Population Segmentation: 1.4.1 Adults; 1.4.2 Adolescents; 1.4.3 Children
1.5 Overweight, Obesity and Morbidity: 1.5.1 The Multifactorial Causes of Obesity; 1.5.1.1 The Appetite Regulatory System?Facts and Theories; 1.5.1.1.1 Insulin; 1.5.1.1.2 Leptin: The Ups and Downs of a Promising Lead; 1.5.1.1.3 Ghrelin; 1.5.1.1.4 Peptide YY & the Y2 Receptor; 1.5.1.1.5 AMPK; 1.5.1.1.6 Role of the Hypothalamus; 1.5.1.1.7 Melanocortins & Serotonin; 1.5.1.2 The Body�fs Fight to Retain Fat; 1.5.1.3 Body Mass Index (BMI); 1.5.1.4 Genetic Roots of Obesity; 1.5.1.4.1 Congenital Leptin Deficiency; 1.5.1.4.2 Genetic Association Studies; 1.5.1.4.3 Genetic Testing For Obesity; 1.5.2 Obesity, Lifestyle and the �eObesogenic�f Environment; 1.5.2.1 Feeding Control; 1.5.2.2 Energy Efficiency; 1.5.2.3 Adipose Tissue Biology; 1.5.2.4 Abdominal Girth as a Warning Sign; 1.5.3 Metabolic Syndrome, or Syndrome X; 1.5.4 Binge Eating Disorder (BED); 1.5.5 Night Eating Syndrome (NES); 1.5.6 Why Treat Obesity?

Section 2: Weight loss management approaches

2.1 Surgical Approaches: 2.1.1 Background and Professional Certification Efforts; 2.1.2 Gastric Bypass, Mini Gastric Bypass and Laparoscopic Surgery; 2.1.2.1 Gastric Bypass, or Roux-en-Y Surgery; 2.1.2.2 Mini Gastric Bypass; 2.1.2.3 Laparoscopic Surgery; 2.1.3 Biliopancreatic Diversion/Duodenal Switch (BPD/DS); 2.1.4 Two-Stage Weight Loss Surgery; 2.1.5 Vertical Banded Gastroplasty (VBG); 2.1.6 Adjustable Gastric Band (AGB) Surgery; 2.1.7 Internal or Implantable Gastric Stimulation (IGS) Device; 2.1.8 Gastric Balloon; 2.1.9 Radio-frequency Antralplasty
2.2 Pharmaceutical Therapies: 2.2.1 Pancreatic Lipase Inhibitors; 2.2.2 Serotonin and Norepinephrine Reuptake Inhibitors; 2.2.3 Noradrenergic Anorectic Agents
2.3 Non-pharmacological Approaches
2.4 Medically Supervised Very Low Calorie Diets (VLCDs), Behavior Modification and Residential Programs
2.5 Weight Maintenance Approaches

Section 3: Impact of obesity

3.1 Obesity Treatments, Related Costs and Reimbursement
3.2 Impact Upon Business/Economy: 3.2.1 United Kingdom; 3.2.2 Impact Upon Insurance Costs; 3.2.3 Cost of Treatment of Obesity, versus Long-term Cost to Treat Related Conditions
3.3 The Government Enters the Fray: 3.3.1 USA; 3.3.1.1 Insurance and Mandated Coverage Bills; 3.3.1.2 Medicare Debates Gastric Bypass Surgery; 3.3.2 United Kingdom: NICE & Weight Management at the Primary Care Level; 3.3.3 France: The Caisse Nationale d�fAssurance Maladie (CNAM)

Section 4: Market Assessment

4.1 Bariatric Surgery Devices: 4.1.1 United States and Canada; 4.1.2 Canada; 4.1.3 European Union; 4.1.3.1 United Kingdom; 4.1.3.2 France; 4.1.3.3 Germany; 4.1.3.4 Italy; 4.1.3.5 Spain; 4.1.3.6 Scandinavia; 4.1.4 Japan; 4.1.5 Rest of World (ROW)
4.2 Pharmaceuticals: 4.2.1 United States and Canada; 4.2.2 Pharmaceutical treatments in the Europe Union; 4.2.2.1 United Kingdom; 4.2.2.2 France; 4.2.2.3 Germany; 4.2.2.4 Italy; 4.2.2.5 Spain; 4.2.2.6 Scandinavia; 4.2.3 Japan; 4.2.4 Rest of World (ROW); 4.2.5 Developing Drugs for Tomorrow, While Maximizing Profits Today

Section 5: Opportunities

5.1 Drug & Device Market Opportunities
5.2 Durable Medical Equipment for the Bariatric Patient
5.3 Creating Mutually Beneficial Relationships
5.4 Focus on Education and Practice Consulting

Section 6: Selected Company Profiles

6.1 Abbott Laboratories
6.2 AdipoGenix
6.3 Amgen
6.4 Amylin Pharmaceuticals
6.5 AstraZeneca
6.6 Athersys, Inc.
6.7 Bayer AG
6.8 Biovitrum AB
6.9 CuraGen Corporation
6.10 DeCODE Genetics
6.11 DeveloGen AG
6.12 Ethicon Endo-Surgery/Johnson & Johnson
6.13 GenWay Biotech, Inc.
6.14 GlaxoSmithKline
6.15 Inamed Corporation
6.16 Ingenium Pharmaceuticals AG
6.17 IntraPace, Inc.
6.18 Johnson & Johnson
6.19 Manhattan Pharmaceuticals, Inc.
6.20 Merck & Co., Inc.
6.21 Metabolic Pharmaceuticals Ltd
6.22 Millennium Pharmaceuticals
6.23 Myriad Genetics
6.24 Nastech Pharmaceutical Company, Inc.
6.25 Pfizer, Inc.
6.26 Regeneron Pharmaceuticals
6.27 Roche (F Hoffman-La Roche Ltd)
6.28 Sanofi-Aventis
6.29 Speedel Group AG
6.30 Synovis Life Technologies Inc.
6.31 Transneuronix, Inc.
6.32 Vista Medical Technologies, Inc.
6.33 Wyeth Pharmaceuticals

Appendix: List of Companies

Appendix: List of ORGANIZATIONS

List of Exhibits

Exhibit 1-1: Elements Contributing to the Obesity Epidemic
Exhibit 1-2: Prevalence of Obesity, Percent of Population (2003)
Exhibit 1-3: WHO Graph of Obesity, 2004
Exhibit 1-4: Worldwide Total, Obese and Morbidly Obese, 2002-2013
Exhibit 1-5: Examples of Definitions Used and Age Groups Included in Surveys Reporting Prevalence of Obesity
Exhibit 1-6: Examples of Human Pleiotropic Obesity Syndromes
Exhibit 1-7: Leptin�fs Role in the Body
Exhibit 1-8: Candidate Genes for Control of Appetite, Energy Expenditure, Usage of Nutrients and Body Fat Distribution
Exhibit 2-1: IFSO and Minimum Professional Requirements for Practicing Bariatric Surgeon
Exhibit 2-2: Gastric Bypass Surgery
Exhibit 4-1: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)
Exhibit 4-2: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)
Exhibit 4-3: Bariatric Surgery Devices, Total Market Forecast, 2002-2013
Exhibit 4-4: Medical Devices, Market Forecast, United States and Canada, 2002-2013
Exhibit 4-5: Bariatric Surgery Devices, Market Forecast, US and Canada, 2002-2013
Exhibit 4-6: US Obesity Treatment Medical Device Company Market Shares, 2013
Exhibit 4-7: Medical Devices, Market Forecast, European Union, 2002-2013
Exhibit 4-8: Medical Devices, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-9: Bariatric Surgery Devices, Market Forecast, United Kingdom 2002-2013
Exhibit 4-10: Medical Devices, Market Forecast, France, 2002-2013
Exhibit 4-11: Bariatric Surgery Devices, Market Forecast, France, 2002-2013
Exhibit 4-12: Adjustable Gastric Band Device Market Shares, France, 2004
Exhibit 4-13: Medical Devices, Market Forecast, Germany, 2002-2013
Exhibit 4-14: Bariatric Surgery Devices, Market Forecast, Germany 2002-2013
Exhibit 4-15: Medical Devices, Market Forecast, Italy, 2002-2013
Exhibit 4-16: Bariatric Surgery Devices, Market Forecast, Italy 2002-2013
Exhibit 4-17: Medical Devices, Market Forecast, Spain, 2002-2013
Exhibit 4-18: Bariatric Surgery Devices, Market Forecast, Spain 2002-2013
Exhibit 4-19: Medical Devices, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-20: Bariatric Surgery Devices, Market Forecast, Scandinavia 2002-2013
Exhibit 4-21: Medical Devices, Market Forecast, Japan, 2002-2013
Exhibit 4-22: Bariatric Surgery Devices, Market Forecast, Japan 2002-2013
Exhibit 4-23: Medical Devices, Market Forecast, Rest of World, 2002-2013
Exhibit 4-24: Bariatric Surgery Devices, Market Forecast, ROW 2002-2013
Exhibit 4-25: Total Pharmaceutical Sales, Market Forecast, 2002-2013
Exhibit 4-26: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
Exhibit 4-27: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
Exhibit 4-28: Obesity Drugs, Market Forecast, European Union, 2002-2013
Exhibit 4-29: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-30: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-31: Obesity Drugs, Market Forecast, France, 2002-2013
Exhibit 4-32: Obesity Drugs, Market Forecast, France, 2002-2013
Exhibit 4-33: Obesity Drugs, Market Forecast, Germany, 2002-2013
Exhibit 4-34: Obesity Drugs, Market Forecast, Germany, 2002-2013
Exhibit 4-35: Obesity Drugs, Market Forecast, Italy, 2002-2013
Exhibit 4-36: Obesity Drugs, Market Forecast, Italy, 2002-2013
Exhibit 4-37: Obesity Drugs, Market Forecast, Spain, 2002-2013
Exhibit 4-38: Obesity Drugs, Market Forecast, Spain, 2002-2013
Exhibit 4-39: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-40: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-41: Obesity Drugs, Market Forecast, Japan, 2002-2013
Exhibit 4-42: Obesity Drugs, Market Forecast, Japan, 2002-2013
Exhibit 4-43: Obesity Drugs, Market Forecast, ROW, 2002-2013
Exhibit 4-44: Obesity Drugs, Market Forecast, ROW, 2002-2013
Exhibit 5-1: Potential Market Alliances in Obesity
Exhibit 6-1: Abbott Laboratories 2003 Sales by Division
Exhibit 6-2: Aventis 2003 Consolidated Sales